公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2021 | Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis | Tan D.S.W.; Geater S.; CHONG-JEN YU ; Tsai C.-M.; Hsia T.-C.; Chen J.; Lin M.-C.; Lu Y.; Sriuranpong V.; Yang C.-T.; Sen P.; Branle F.; Shi M.; Wu Y.-L. | JTO Clinical and Research Reports | 5 | 0 | |
2016 | Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status | Hsu C.-H.; Tseng C.-H.; CHUN-JU CHIANG ; Hsu K.-H.; Tseng J.-S.; Chen K.-C.; Wang C.-L.; Chen C.-Y.; Yen S.-H.; Chiu C.-H.; Huang M.-S.; CHONG-JEN YU ; Tsai Y.-H.; JIN-SHING CHEN ; Tsai C.-M.; Chou T.-Y.; Lin K.-C.; Tsai M.-H.; WEN-CHUNG LEE ; Ku H.-Y.; Liu T.-W.; Yang T.-Y.; Chang G.-C. | Oncotarget | 38 | 30 | |
2015 | Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: A combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 | CHIH-HSIN YANG ; Sequist L.V.; Geater S.L.; Tsai C.-M.; Mok T.S.K.; Schuler M.; Yamamoto N.; CHONG-JEN YU ; Ou S.H.I.; Zhou C.; Massey D.; Zazulina V.; Wu Y.-L. | The Lancet Oncology | 778 | 644 | |
2011 | Different efficacies of erlotinib and gefitinib in Taiwanese patients with advanced non-small cell lung cancer: A retrospective multicenter study | Fan W.-C.; CHONG-JEN YU ; Tsai C.-M.; Huang M.-S.; Lai C.-L.; Hsia T.-C.; Tien Y.-J.; Huang S.-F.; Wu C.-H.; Chou K.-T.; Lee Y.-C.; Perng R.-P.; Chen Y.-M. | Journal of Thoracic Oncology | 24 | 21 | |
2015 | Epidermal growth factor receptor tyrosine Kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/S768I mutations | Chiu C.-H.; Yang C.-T.; JIN-YUAN SHIH ; Huang M.-S.; Su W.-C.; Lai R.-S.; Wang C.-C.; Hsiao S.-H.; Lin Y.-C.; Ho C.-L.; Hsia T.-C.; Wu M.-F.; Lai C.-L.; Lee K.-Y.; Lin C.-B.; Yu-Wung Yeh D.; Chuang C.-Y.; Chang F.-K.; Tsai C.-M.; Perng R.-P.; Chih-Hsin CHIH-HSIN YANG | Journal of Thoracic Oncology | 207 | 169 | |
2021 | Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations | Chang G.-C.; Lam D.C.-L.; Tsai C.-M.; Chen Y.-M.; JIN-YUAN SHIH ; Aggarwal S.; Wang S.; Kim S.-W.; Kim Y.-C.; Wahid I.; Li R.; Lim D.W.-T.; Sriuranpong V.; Chan R.T.-T.; Lorence R.M.; Carriere P.; Raabe C.; Cseh A.; Park K. | International Journal of Clinical Oncology | 2 | 2 | |
2008 | Fatigue experience and coping strategies in Taiwanese lung cancer patients receiving chemotherapy | YUN-HSIANG LEE ; Tsai Y.-F.; YEUR-HUR LAI ; Tsai C.-M. | Journal of Clinical Nursing | 13 | 12 | |
2020 | Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC | Nishio M.; Felip E.; Orlov S.; Park K.; CHONG-JEN YU ; Tsai C.-M.; Cobo M.; McKeage M.; Su W.-C.; Mok T.; Scagliotti G.V.; Spigel D.R.; Viraswami-Appanna K.; Chen Z.; Passos V.Q.; Shaw A.T. | Journal of Thoracic Oncology | 26 | 19 | |
2017 | First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study | Soria J.-C.; Tan D.S.W.; Chiari R.; Wu Y.-L.; Paz-Ares L.; Wolf J.; Geater S.L.; Orlov S.; Cortinovis D.; CHONG-JEN YU ; Hochmair M.; Cortot A.B.; Tsai C.-M.; Moro-Sibilot D.; Campelo R.G.; McCulloch T.; Sen P.; Dugan M.; Pantano S.; Branle F.; Massacesi C.; de Castro G.; Jr | The Lancet | 901 | 771 | |
2016 | First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer the ASPIRATION study | Park K.; CHONG-JEN YU ; Kim S.-W.; Lin M.-C.; Sriuranpong V.; Tsai C.-M.; Lee J.-S.; Kang J.-H.; Chan K.C.A.; Perez-Moreno P.; Button P.; Ahn M.-J.; Mok T. | JAMA Oncology | 200 | 164 | |
2014 | First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial | CHIH-HSIN YANG ; Kang J.H.; Mok T.; Ahn M.-J.; Srimuninnimit V.; CHIA-CHI LIN ; Kim D.-W.; Tsai C.-M.; Barraclough H.; Altug S.; Orlando M.; Park K. | European Journal of Cancer | 41 | 40 | |
2007 | The hyperkeratotic variant of disseminated superficial actinic porokeratosis - A prurigo simulator | Tsai C.-M.; TSEN-FANG TSAI ; Kuo F.-S.; Chen Y.-F.; Hung C.-M. | Dermatologica Sinica | 0 | ||
2006 | Interstitial mycosis fungoides - A cases report and literature review | Tsai C.-M.; TSEN-FANG TSAI ; Chen Y.-F.; Hung C.-M. | Dermatologica Sinica | 0 | ||
2016 | Iron Pyrite/Titanium Dioxide Photoanode for Extended Near Infrared Light Harvesting in a Photoelectrochemical Cell | Wang D.-Y.; Li C.-H.; Li S.-S.; Kuo T.-R.; Tsai C.-M.; Chen T.-R.; Wang Y.-C.; Chen C.-W.; Chen C.-C.; CHUN-WEI CHEN | Scientific Reports | |||
2006 | A large elevated tumor on the back of a 78-year-old man | Tsai C.-M.; TSEN-FANG TSAI ; Chen Y.-F.; Hung C.-M. | Dermatologica Sinica | 0 | ||
2007 | A phase II study of oral vinorelbine in combination with cisplatin conducted in Taiwan in patients with unresectable localized or metastatic non-small cell lung carcinoma | Chen Y.-M.; CHONG-JEN YU ; CHIH-HSIN YANG ; Perng R.-P.; Tsai C.-M.; Shih J.-F.; ANN-LII CHENG ; Lefresne F.; Barbier M.; Pouget J.-C.; PAN-CHYR YANG | Lung Cancer | 14 | 12 | |
2006 | Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients | Chang G.-C.; Tsai C.-M.; Chen K.-C.; CHONG-JEN YU ; JIN-YUAN SHIH ; Yang T.-Y.; Lin C.-P.; Hsu J.-Y.; Chiu C.-H.; Perng R.-P.; PAN-CHYR YANG ; CHIH-HSIN YANG | Journal of Thoracic Oncology | 44 | 35 | |
2017 | Preliminary contractual framework for BIM-enabled projects | Chong H.-Y.; Fan S.-L.; Sutrisna M.; Hsieh S.-H. ; Tsai C.-M. | Journal of Construction Engineering | 61 | 49 | |
2014 | A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER) | Shi Y.; Au J.S.-K.; Thongprasert S.; Srinivasan S.; Tsai C.-M.; Khoa M.T.; Heeroma K.; Itoh Y.; Cornelio G.; PAN-CHYR YANG | Journal of Thoracic Oncology | 1087 | 977 | |
2007 | Revisit of 1997 TNM staging system - Survival analysis of 1112 lung cancer patients in Taiwan | Perng R.-P.; Chen C.-Y.; Chang G.-C.; Hsia T.-C.; Hsu N.-Y.; Tsai Y.-H.; Tsai C.-M.; CHIH-HSIN YANG ; Chen Y.-M.; CHONG-JEN YU ; Lee J.-J.; Hsu H.-S.; Yu C.-T.; Kao E.-L.; Chiu C.-H. | Japanese Journal of Clinical Oncology | 12 | 7 |